Big news from Tribune Tx! We're excited to announce our new discovery and development collaboration with Eli Lilly. A big thanks to the teams on both sides for making this happen. Combining Eli Lilly’s expertise in drug discovery and development with our unique insight into CCN biology holds great promise for our mission to treat fibrosis no matter the cause. We are more than eager to get started on working together with Lilly in this important collaboration. Stay tuned for updates as we continue to unravel CCN biology and make new strides towards better treatments for patients with fibrotic diseases. #Biotech #Innovation #Collaboration #EliLilly #Tribunetx
About us
Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.
- Website
-
http://tribunetx.com
External link for Tribune Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2020
Employees at Tribune Therapeutics
Updates
-
Our CEO, Georg Vo Beiske is presenting at BioEquity on Monday at 11:30 in Room 9. Make sure to stop by for a quick update on Tribune Tx or catch us later at the conference.
I am presenting at BioEquity Europe - hope to see you there!
-
We are thrilled to announce that two esteemed professionals are joining our mission - **Dr. Lars Erwig** and **Prof. Toby Maher**. With their vast experience and unique perspectives, they will undoubtedly bring valuable insights in their roles as scientific advisers. Their expertise will be instrumental in guiding our research and development efforts, ensuring we continue making strides towards new treatments for fibrotic diseases. Please join us in extending a warm welcome to Dr. Lars Erwig and Prof. Toby Maher. We look forward to their contributions and are excited about the future of Tribune Therapeutics with them on board. #TribuneTherapeutics #Welcome
-
-
We are proud to welcome Vibeke as our 6th employee in Norway. She brings great expertise and experience with her to Tribune Tx and we can't wait to start working together towards our next milestone!
I'm so happy to share that I have started in a position as Principal Scientist at #Tribune Therapeutics today!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Big news from Tribune Tx! We're thrilled to announce our new CMC collaboration with industry leader Bayer. This partnership accelerates our mission to treat fibrosis no matter the cause. Our combined expertise in drug development and Bayer’s experience in biologic manufacturing is a perfect match to drive innovation. Thanks to our dedicated team and Bayer’s BioPartnering Solutions for this incredible opportunity! Stay tuned for updates as we embark on this transformative journey in biotech and therapeutics. #Biotech #Innovation #Collaboration #Bayer #Tribunetx